Scientists in Germany have developed a new blood test that may help doctors detect Alzheimer’s disease and Parkinson’s disease long before patients begin showing symptoms.
Researchers believe this breakthrough could completely change how these serious brain diseases are diagnosed and treated in the future.
The research was led by Professor Klaus Gerwert from Ruhr University Bochum in Germany. The study was featured as the cover story in the April 24, 2026 issue of The Journal of Physical Chemistry B.
For many years, doctors have struggled with one major problem when treating Alzheimer’s and Parkinson’s disease. By the time patients begin to notice memory loss, confusion, tremors, or movement problems, the brain has often already suffered severe and permanent damage.
Alzheimer’s disease is the most common form of dementia. It slowly destroys memory, thinking ability, and everyday functioning. Parkinson’s disease mainly affects movement and can cause shaking, stiffness, and balance problems. Both conditions become much more common as people grow older.
As populations continue aging around the world, the number of people living with these diseases is increasing rapidly. This creates emotional pain for patients and families and also places enormous pressure on healthcare systems.
Although scientists have recently developed new medicines that may help slow Alzheimer’s disease, experts say treatment works best when started very early. The same is true for Parkinson’s disease. Doctors believe future treatments may become far more effective if patients can be diagnosed before large areas of the brain are damaged.
This is why researchers have been searching for simple ways to detect these diseases earlier. A blood test would be especially useful because it could potentially become part of routine health screening during middle age or older adulthood.
The new test developed by the Ruhr University Bochum team works by identifying tiny changes in proteins inside the blood. These protein changes happen many years before symptoms appear.
In Alzheimer’s disease, a protein called amyloid beta begins to fold incorrectly and form sticky clumps inside the brain known as amyloid plaques. In Parkinson’s disease, another protein called alpha-synuclein becomes damaged and forms clumps called Lewy bodies.
Scientists now believe these abnormal protein changes may begin developing decades before a person notices symptoms.
The new blood test uses highly specific antibodies to pull these damaged proteins out of blood samples. After the proteins are isolated, the researchers use advanced infrared laser technology to study whether the proteins are folded normally or abnormally.
The researchers developed a special surface coating that allows the sensor to capture only the target proteins while blocking unwanted materials from interfering with the results. This makes the test more accurate when working with complicated body fluids such as blood.
The system also uses difference spectroscopy, a highly sensitive method that allows scientists to separate tiny molecular signals from background noise. According to the researchers, this combination of biology, physics, chemistry, and laser technology made the breakthrough possible.
Lead author Dr. Grischa Gerwert explained that one major advantage of the technology is scalability. The laser system can potentially run many tests at the same time, which could make it suitable for large hospitals and population-wide screening in the future.
The blood test is already being used in clinical studies through a company called BetaSENSE, which was founded by the research team. The company is currently working with pharmaceutical companies to study new treatments, including a vaccine being developed for Parkinson’s disease.
Before the blood test can become widely available to the public, it must still go through strict approval processes under European medical regulations. This requires extensive testing, safety checks, and financial investment.
The researchers say they are working hard to move the approval process forward so the test may eventually become available for early screening.
The study represents an exciting step toward earlier diagnosis of neurodegenerative diseases. Detecting Alzheimer’s and Parkinson’s before symptoms begin could give doctors a much larger window of time to start treatment, monitor patients, and possibly slow disease progression.
However, some challenges still remain. Researchers must confirm that the test works accurately across very large populations and different age groups. Scientists also need to understand how early treatment should begin once abnormal proteins are detected.
Still, many experts believe this research could become one of the most important advances in brain disease detection in recent years. A simple blood test that identifies these conditions before symptoms appear could eventually transform preventive medicine and improve quality of life for millions of people.
If you care about Parkinson’s disease, please read studies that Vitamin B may slow down cognitive decline, and Mediterranean diet could help lower risk of Parkinson’s.
For more information about brain health, please see recent studies that blueberry supplements may prevent cognitive decline, and results showing Plant-based diets could protect cognitive health from air pollution.
Source: Ruhr University Bochum.
